Researchers, publishing in Toxicology Research, review the evidence that antidepressant exposure in the womb is linked to autism spectrum disorders (ASD) in humans.
Research illustrates privacy concerns with how mental health applications collect and share users’ data.
A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.
Industry-funded continuing medical education (CME) influences physicians to prescribe more opioids, focus less on the consequences.
Researchers question biases of preliminary trials that found that sodium nitroprusside, an antihypertensive drug, has positive effects on schizophrenia symptoms.
New study finds that antidepressants may negatively impact recovery after psychiatric hospitalization.
Twice as many teenagers with ADHD experienced severe psychosis when taking Adderall, as compared to Ritalin, according to a new study.
Peer-Support Groups Were Right, Guidelines Were Wrong: Dr. Mark Horowitz on Tapering Off Antidepressants
In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.
Researchers examine psychiatrist-client interactions and find that clients are often left with few opportunities to make explicit requests to change their medication regimen.
A new article in Lancet Psychiatry finds that slower tapering of SSRIs is better for preventing antidepressant withdrawal effects.
European citizens from 27 different countries will soon go to the polls to elect their representatives in the European Parliament for the next five years. As an advocacy organisation, we see those elections as an opportunity to call on current and future European leaders and policymakers to bring mental health to the heart of European policies.
“Converging lines of evidence now suggest that depression—a common comorbidity in the setting of chronic pain—may in some patients represent an unrecognized yet potentially reversible harm of opioid therapy.”
Researchers question the overstated results of a large antidepressant meta-analysis and point to cultural pressures to turn to these drugs for a quick fix.
Researchers identify simple ways for clinicians to begin deprescribing conversations.
John Ioannidis, a leading expert on research methods, takes a critical look at the way professional societies write treatment guidelines.
Dr. Dainius Pūras argues that the status quo in mental health treatment is no longer acceptable and demands political action to promote human rights.
Attempting to locate the mechanisms of psychiatric disorder is a step in the wrong direction and fails to challenge potentially unjust social practices.
A new paper explores how the disputed nature of psychiatric knowledge influences public perceptions and debates within the field of mental health.
A new study examines the benefits of collaborating with mental health consumers in research.
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
An international group of researchers, including several with financial ties to manufacturers of antidepressants, explore possible explanations for why long-term users of antidepressants become chronically depressed.
In a MIA survey of people who had been patients in mental hospitals, nearly 500 respondents told of an experience that was often traumatic, and frequently characterized by a violation of their legal rights, forced treatment with drugs, and physical or sexual abuse. Only 17% said they were “satisfied” with the “quality of the psychiatric treatment” they received.
Benzodiazepine prescription practices may be in response to an epidemic of distress, rather than being used to treat specific mental health diagnoses.
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
Reforming the process of real informed consent can be brought to the horizon sooner rather than later if we have a solid idea of what the provision of truthful, unbiased research-based information about psychiatric medications should look like. Our upcoming series of webinars for 2019 will focus on just that.